Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to those taking semaglutide 1 mg At the lowest dose of tirzepatide (5 mg), participants achieved A1C

- Baricitinib met primary endpoint of hair regrowth across both dosing regimens - There are currently no FDA-approved treatments for AA INDIANAPOLIS , March 3, 2021 /PRNewswire/ --  Eli Lilly and Company  (NYSE: LLY) and  Incyte  (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a

INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received

COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly 's connected insulin solutions, currently in development.